We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Eoin Flanagan MB, BCh

Eoin P. Flanagan MB, BCh

Associate Professor of Neurology and Consultant in the Departments of Neurology and Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota

Dr. Eoin Flanagan is an Associate Professor of Neurology and Consultant in the departments of Neurology and Laboratory Medicine and Pathology at the Mayo Clinic (Rochester, MN). He completed his medical school training at University College Dublin in Ireland in 2005. He completed medical residency in Ireland and became a member of the Royal College of Physicians of Ireland in 2008. He then pursued neurology residency at Mayo Clinic (Rochester, MN) and is board certified in neurology in the USA. He completed fellowships in autoimmune neurology, multiple sclerosis and behavioral neurology at Mayo Clinic. He received a Master’s degree in clinical and translational science at Mayo Clinic. He works in the Autoimmune and Multiple Sclerosis Neurology Clinics and the Neuroimmunology Laboratory at the Mayo Clinic. His clinical expertise and research is focused on the diagnosis and management of autoimmune neurological disorders with an emphasis on inflammatory autoimmune spinal cord disorders and their mimics including their MRI patterns. He also has an interest in the epidemiology of inflammatory demyelinating diseases of the central nervous system and autoimmune neurologic disorders.


Dr. Flanagan is a site principal investigator in a randomized placebo-controlled clinical trial of Inebilizumab (A CD19 inhibitor) in neuromyelitis optica spectrum disorders funded by MedImmune/Viela Bio. He receives no personal compensation and just receives reimbursement for the research activities related to the trial.